ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mylan Confronts Teva, Perrigo Buys From GSK

by Ann M. Thayer
June 8, 2015 | APPEARED IN VOLUME 93, ISSUE 23

Six weeks after Israel’s Teva Pharmaceutical Industries made an unsolicited bid for Mylan, Mylan’s chairman says it’s time for Teva to “stop playing games” and either make a serious offer or leave it alone. According to Mylan, Teva’s purchases of Mylan shares on the open market possibly violate of U.S. antitrust laws. In any case, Teva’s actions have complicated Mylan’s attempt to acquire Ireland-based Perrigo. Meanwhile, Perrigo, which has rejected Mylan’s offers, is acquiring over-the-counter drugs from GlaxoSmithKline. With annual sales of $110 million, the products are being divested to satisfy regulators as GSK forms a consumer health joint venture with Novartis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment